Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to a nutritional approach for moderating the effect of enterotoxins resulting from infection by pathogens.
• Human and animal gastrointestinal tract is at risk to develop various disorders, including these caused by aging, viruses, bacteria and/or their toxins or by physical and chemical abuses, among others.
• RU 2168915 discloses the use of a meat product comprising predetermined ratios of beef, pork, blanched beef liver, squash or pumpkin, and butter as a curing or preventing food product against gastrointestinal disorders in children and weak people. All the above observations indicate that the field of nutritional intervention against C. difficile infection is still open.
• the present invention relates to the use of an oral composition comprising yeast extract to treat the effects of enterotoxins resulting from infection by pathogens.
• Such effects include failure of gut epithelial integrity due to the disassembly of actin filaments and the resulting disruption of tight junctions as well as diarrhoea resulting from toxin-induced secretion of intestinal fluid and other processes mediated by cyclooxygenase induction.
• oral composition is intended to mean any ingestible composition, and may be a nutritional composition, a nutritional supplement, or a medicine. It may also be the adjuvant of a medicinal treatment, for example. It is intended to be used in humans, from infants or pre-termed infants to elderly people, suffering from the effects of enterotoxins resulting from infection by pathogens. It is also intended for pets, such as cats, dogs, fish, rabbits, mice, hamsters and the like, and more generally for any animal being bred by humans, such as horses, cows, fowl, sheep etc, suffering from the effects of enterotoxins resulting from infection by pathogens.
• yeast extract may include the water-soluble portion of autolysed yeast, and preferably contains vitamin B complexes. It is also intended to cover an extract comprising both soluble and insoluble portions of autolysed bakers' yeast, and in this case it preferably further comprises riboflavin and panthotenic acid. However, in the preferred embodiment of the present invention, the “yeast extract” does not encompass the microorganism and does not comprise the enzymes produced by the microorganism.
• the yeast extract may be an extract from Saccharomyces cerevisiae.
• An example of a suitable, commercially available yeast extract for use in the present invention is BD Bacto Yeast Extract supplied by Becton Dickinson and Company
• meat extract is intended to cover extracts of any meat, such as beef, pork, lamb, chicken and/or turkey, among others. It may also be from a mixture of the above-cited meats. In any event, it will provide at least nitrogen, amino acids, and carbon.
• a suitable, commercially available meat extract for use in the present invention is BD Bacto Beef Extract supplied by Becton Dickinson and Company.
• peptone means any soluble mixture of products produced by the partial enzymatic or acid hydrolysis of proteinaceous material.
• the choice of protein starting material is not critical but casein, whey and meat proteins are preferred.
• the peptones have molecular weights of less than 3 kDa
• An example of a suitable, commercially available peptone for use in the present invention is BD Bacto Peptone supplied by Becton Dickinson and Company
• Enterotoxins are bacterial exotoxins that have an action upon the intestinal mucosa. They may be produced within the intestine by pathogenic bacteria. Bacterial enterotoxins are potent mucosal immunogens that activate both mucosal and systemic immune responses and thus are the cause of various diseases, which include food poisoning, common diarrhoea, colitis, chronic inflammation and dysentery. Enterotoxins also lead to serious mucosal ulceration, haemorrhagic inflammatory exude or bloody diarrhoea. Toxin-induced diseases are often accompanied by abdominal cramps and rectal pain. Enterotoxins are the main stimulators of fluid secretion and intestinal inflamimation.
• Toxins also induce severe inflammation, usually characterized by transmigration of neutrophils in the mucosa and enterocyte necrosis, via the activation of sensory enteric nerves and the release of sensory neuropeptides, followed by release of cytokines and epithelial cell destruction.
• Pathogenic bacteria may be part of the commensal microflora, that is may exist in the gut without harmful effect unless and until the balance of the microflora is disturbed as may happen, for example, during treatment with antibiotics, particularly broad spectrum antibiotics. In such circumstances, these “opportunistic pathogens” may grow rapidly, coming to dominate the intestinal microflora and produce toxins which cause enteritis. Examples of such bacteria include Clostridium difficile and Clostridium perfringens and the compositions of the invention are particularly well suited to treating the effects of toxins produced by such bacteria. It will be appreciated that the invention is thus particularly suitable for use in the treatment of nosocomial infections.
• enterotoxin-producing bacteria examples include E. coli, Leishmania donovani, Vibrio cholera, Salmonella typhimurium, Shingellae, Aeromonas hydrophila, Staphylococcus aureus, or enterotoxigenic Bacteroides fragilis (ETBF).
• Clostridiuyn difficile infection is the main cause of colitis and diarrhoea in hospitalised patients, whose intestinal microbiota is altered due to antibiotics uptake.
• C. difficile causes enteritis by releasing two enterotoxins: toxin A and toxin B. Both toxins have a potent cytotoxic effect in humans but toxin A is the main stimulator of fluid secretion (therefore diarrhoea) and intestinal inflammation. Toxin A binds on the surface of epithelial cells, and it is internalised into the cytoplasm in coated pits.
• Diarrhoea is the result of increased secretions from the epithelial cells in the gut which may be induced by pathogenic bacteria (including enterotoxin-producing bacteria), parasites or viruses.
• COX-2 is an enzyme catalyzing the synthesis of prostaglandins from arachidonic acid.
• Other known substrates for COX-2 include dihomo-gamma-linolenic acid (20:3n:6) and eicosapentaenoic acid (EPA, 20:5n-3) producing PGE 1 and PGE 3 , respectively.
• the human COX-2 gene has been cloned and its genomic pattern and the responsiveness of its gene expression to different elements, such as cAMP, NF- ⁇ B and TGF- ⁇ , IL-1 or TNF- ⁇ has been described.
• COX-2 is linked to numerous inflammations, including allergic reactions and gut inflammations. Among gut inflammations and disorders, wherein COX-2 activity is involved, are gastritis, inflammatory bowel disease, irritable bowel syndrome, or intestinal cancers.
• the yeast extract is given in form of an oral composition comprising, in volume, from 0.01 to 0.5% yeast extract.
• the composition may include peptones, preferably in an amount of 0.3 to 7%. Suitable sources of peptones include whey protein and an extensively hydrolysed whey protein with an average peptide size not greater than five amino acids is particularly preferred although whey proteins with a degree of hydrolysis between 15 and 20% may also be used. Meat proteins are an alternative source of peptones and among meat proteins, beef proteins are preferred.
• the composition may also include meat extract, preferably in an amount of from 0.3 to 7.0% by volume.
• the oral composition comprises (in volume) 0.5% yeast extract, 1% of meat extract and 1% peptones.
• the oral composition of the invention may take the form of various different food products.
• it can be an infant formula powder when the target population is an infant population.
• It can also be a dehydrated food products, such as soups.
• It can further be an enteral composition or supplement formulas.
• the oral composition can be any wet or dry pet food.
• composition when the composition, according to the invention, is incorporated into a medicine, it can be incorporated together with any appropriate excipient to any medicinal form.
• yeast extracts by ingesting yeast extracts, individuals suffering from infection by pathogens as evidenced by intestinal disorders such as failure of gut epithelial integrity and diarrhoea have a normalised fluid secretion, a cellular structure less damaged, and a decreased inflammation compared to individuals having the same disorders, but a diet not supplemented with yeast extracts.
• peptone and/or meat extract may also be associated with yeast extract to obtain an improved effect on gut integrity into individuals subjected to gut upsets, damages and stresses.
• the human colonic cell line T8 4 (ATCC, CCL-248) was cultured in DMEM:F12 1:1 supplemented with 20% FBS (Foetal Bovine Serum), 2 mM glutamine and 100 U/ml penicillin-streptomycin.
• Human primary skin fibroblasts were cultured in DMEM supplemented with 10% FBS and 100 U/ml penicillin-streptomycin.
• T8 4 monolayers were seeded in 6-well inserts plates at 0.5 ⁇ 10 6 cells/insert and cultured during 3 weeks.
• the basal value of the TEER Transepithelial Electrical resistance
• culture medium was replaced by 20% of a solution of de Man-Rogosa-Sharpe growth medium (a solution containing 0.5% yeast extract with 1% beef extract and 1% meat peptones in PBS hereinafter referred to as “MRS”).
• MRS de Man-Rogosa-Sharpe growth medium
• C. difficile toxin A was added in the apical side of the monolayers at a final concentration of 100 ng/ml and the TEER were further measured after 1, 2, 4, 6 and 24 h at 37° C.
• Control monolayers were exposed to cultured media only. For each condition triplicate inserts were used. At each time point, 1 ml apical and 1 ml basoiateral medium was collected and vat viability was evaluated by measuring the LDH release using the Cytotoxicity Detection Kit according to the manufacturers, instructions.
• T84 cells or human primary fibroblasts (2 ⁇ 10 5 /chamber) were seeded on 4-chamber glass slides, grown as described previously and incubated with a 20% solution of MRS for 1 h before addition of toxin A at a final concentration of 500 ng/ml. After 6 h, cells were washed with PBS, fixed with 3.7% paraformaldehyde, washed twice with PBS, permeabilized for 5 min at ⁇ 20° C. with acetone and treated with PBS-1% BSA (Bovine Serum Albumin) to reduce non-specific labelling. Actin desegregation and cell rounding were assessed by fluorescent microscopy after labelling with 200 U/ml rhodamine-labelled phallotoxin.
• BSA Bovine Serum Albumin
• Toxin A affects tight junctions of epithelial cells, an effect which is measured by the decrease of the transepithelial electrical resistance (TEER) of epithelial monolayers.
• TEER transepithelial electrical resistance
• T84 cells were treated with toxin A alone or in combination with a 20% solution of MRS and cytoskeletal actin was analysed by immunocytochemistry. Addition of 500 ng/ml toxin A induced T84 cell rounding, which is evidenced by the bee nest appearance of the cell monolayer due to actin desegregation, and packaging. Addition of a 20% solution of MRS in combination with toxin A partially prevented actin desegregation and subsequent cell rounding induced by toxin A, while it did not influence the cytoskeleton of the cells when added alone.
• Toxin A induces polymerisation of actin filaments, leading to desegregation of cytoskeletal actin.
• Actin disruption is the cause of cell rounding, observed in vitro, and increased permeability of the tight junctions.
• the toxin A effect on actin is due to its glucotransferase activity against the Rho fanily of proteins.
• Toxin A is able to enzymaticaly transfer a glucosyl residue from UDP glucose to threonine 37 of Rho, Rac and Cdc-42, leading to disassembly of actin stress fibers, disruption of the actin-associated adhesion plaque, opening of the tight junctions, cell detachment and increased fluid secretion.
• Those effects have been demonstrated in vitro on T84 cells, where addition of toxin A on the monolayer diminished the transepithelial resistance and increased the permeability of the monolayer, due to modifications of the Rho proteins in the epithelial cells. Therefore we believe that yeast extract interferes with the signalling pathway of the Rho proteins, inhibiting the effects of toxin A. Although not wishing to be bound by theory, this interference could be up-stream or down-stream of the transfer of the glucosyl residue to Rho proteins.
• mice Six weeks old male mice were treated ad libitum with 60 mg/L gentamicin, 250 mg/L vancomycin, 300 mg/L amoxicillin and 10 mg/L amphotericin for a week in order to eliminate the intestinal microbiota. Mice were then divided into three groups: i) a control group; ii) a group receiving ad libitum a 20% solution of MRS in the drinking water, for a week; and iii) a group that was gavaged twice with 500 ⁇ l the composition at two day interval.
• mice were anaesthetized with 30 mg/kg of body weight sodium pentobarbital and placed on a warm blanket (37° C.), under 0.8-3% isofluoran anaesthesia for the whole duration of the operation.
• the abdomen was opened by a midline incision and the distal jejunum was exposed.
• Two 5 cm jejunal segments were doubly ligated at each end with surgical thread to form two intestinal loops with a 2 cm interval between them.
• One loop was injected with 600 ⁇ l PBS as a control and the other with 600 ⁇ l PBS containing 20 ⁇ g toxin A.
• the intestinal loop was then returned to the abdominal cavity and the incision was sutured closed. Mice were allowed to recover and they were followed continously.
• Loops were isolated and their weight to length ratio (in mg/cm) was recorded to estimate fluid secretion. Loops were then washed twice with ice cold PBS, dipped in RNAlaterTM, flashed frozen in liquid nitrogen and stored at ⁇ 80° C.
• C. difficile infection leading to diarrhoea and colitis, develops mostly in hospitals and elderly people's homes striking patients who take antibiotics and thus their intestinal microbiota is altered.
• a mouse model was used. To mimic the conditions that trigger C. difficile infection in humans, mice were treated for a week with antibiotics aimed to alter their intestinal microbiota. One day after the end of antibiotic treatment, a group of mice were given the 20% solution of MRS ad libitum for one week. At the end of this period, intestinal loops were formed and injected with PBS or 20 ⁇ g toxin A.
• the 20% MRS solution, or PBS as a control were mixed with toxin A 1 h before injecting the mixture in the intestinal loops of mice, treated for a week with antibiotics. There was not a significant difference recorded between control (PBS) and the MRS-injected loops at the level of toxin A-induced fluid secretion. This result indicates that the composition does not counteract the effects of toxin A via direct binding and inactivation of the toxin, which could lead to either toxin-cleavage or masking of the toxin-binding epitopes.
• the MRS composition protected the mice from intestinal fluid secretion induced by toxin A.
• the protective action of yeast extract is not due to an enzymatic activity, which cleaves toxin A for two main reasons: i) The solutions used were always autoclaved, which would lead to disactivation of any enzymes, such as proteases, contained in the solution and ii) The composition mixed and incubated with toxin A before being injected in the intestinal loops of mice, could not inhibit intestinal fluid secretion. Therefore we do believe that the protective activity of yeast extract is due to the presence of free molecules in the solution (e.g. aminoacids or peptides), which could bind on the toxin A receptor on the intestinal epithelial cells and prevent binding of toxin A and the activation of the signalling pathways involved.
• free molecules in the solution e.g. aminoacids or peptides
• RNA was extracted from mouse intestinal loops, and COX-2 mRNA expression was assessed by RT-PCR.
• Total RNA (1 ⁇ g) was reverse transcribed with 200 U of Superscript II® enzyme.
• a 400 bp fragment of mouse COX-2 was amplified by PCR using 5′-CACAGTACACTACATCCTGACC-3′ as sense and 5′-TCCTCGCTTCTGATTCTGTCTTG-3′ as antisense primers.
• PCR was performed directly on RNA samples. PCR products were loaded on 1% agarose gel, photographed, and pictures used for densitometrical quantification of band intensities. Normalization was performed against the expression of the internal control ⁇ -actin: the ratios of the COX-2 and the corresponding ⁇ -actin mRNA signals were determined and expressed relative to that of the “not-treated sample” (given water and injected with PBS) to which an arbitrary score of 1 was assigned.
• COX-2 known to be involved in toxin A-mediated fluid secretion
• COX-2 mRNA expression was assessed by RT-PCR. Changes in COX-2 expression due to different treatments were expressed relative to ⁇ -actin. Injection of 20 ⁇ g toxin A in the intestinal loops of control mice resulted in a 3.6-fold increase of COX-2 mRNA expression. Treatment of mice for one week with the MRS composition resulted in a 2-fold reduction of the COX-2 increase mediated by toxin A. Intestinal COX-2 expression induced by toxin A was decreased by 2.3-fold under yeast extract treatment. Neither MRS nor yeast extract atone significantly modified the basal levels of COX-2 mRNA expression. When given by gavage, the MRS and its component yeast extract alone were also able to counteract the increase in COX-2 mRNA induced by toxin A.
• toxin A When toxin A binds on the epithelial cells it is shown to induce inflammation, including neutrophil migration and enterocyte necrosis and destruction of the villus. These effects are mediated by the release of sensory neuropeptides, such as substance P and calcitonin gene-related peptide, following the activation of sensory enteric nerves.
• sensory neuropeptides such as substance P and calcitonin gene-related peptide
• the receptor for SP significantly increases both in animals and in humans infected with C. difficile .
• toxin A of C. difficile upregulates expression of COX-2 in the intestine.
• COX-2 is the inducible isoform of the cyclooxygenase enzyme, which mediates synthesis of prostaglandin E2 (PGE2) an agent known to increase intestinal fluid secretion, which leads to diarrhoea.
• PGE2 prostaglandin E2
• yeast extract inhibits any of these pathways counteracting toxin A.
• yeast extract inhibits intestinal, toxin-mediated, COX-2 induction. This could be due to inhibition of toxin A-mediated signalling, which leads to COX-2 activation if our solutions inhibit or reduce binding of the toxin on its intestinal receptor.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Mycology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Microbiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Biotechnology (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Epidemiology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=34354432

Family Applications (2)

Family Applications After (1)

Country Status (10)

Cited By (1)

Families Citing this family (2)

Citations (1)

Family Cites Families (14)

• 2004
  • 2004-10-13 BR BRPI0415388-0A patent/BRPI0415388A/pt not_active IP Right Cessation
  • 2004-10-13 US US10/595,396 patent/US20060292171A1/en not_active Abandoned
  • 2004-10-13 CN CNA2004800369434A patent/CN1889966A/zh active Pending
  • 2004-10-13 WO PCT/EP2004/011470 patent/WO2005039609A2/en active Application Filing
  • 2004-10-13 CA CA002542452A patent/CA2542452A1/en not_active Abandoned
  • 2004-10-13 TW TW093131136A patent/TW200520767A/zh unknown
  • 2004-10-13 EP EP04790343A patent/EP1689417A2/en not_active Withdrawn
  • 2004-10-13 AR ARP040103710A patent/AR046107A1/es not_active Application Discontinuation
  • 2004-10-13 JP JP2006534671A patent/JP2007508342A/ja not_active Withdrawn
• 2006
  • 2006-04-20 IL IL175080A patent/IL175080A0/en unknown
• 2009
  • 2009-06-12 US US12/483,861 patent/US20100028316A1/en not_active Abandoned

Patent Citations (1)

Also Published As

Similar Documents

Legal Events